4 randomised control trials were included in this meta-analysis, to compare the effectiveness of 60mg Denosumab subcutaneously per 6 months (Den) to 70mg Alendronate orally per week (Aln) in the treatment of osteoporosis in postmenopausal women. A total of 1952 women were identified that were followed-up for one year. The primary outcomes were the incidence of clinical fractures and bone mineral density at different sites. The results from the analysis indicated that Den treatment increased bone mineral density without higher incidence of adverse events in comparison to Aln treatment, but did not reduce the risk of fracture.